Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × amivantamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17 Stomach Neoplasms 1 Solid Tumors 1 Salivary Gland Neoplasms 1 RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Non-small Cell Lung Cancers 1 Lung Neoplasms 1 Locally Recurrent Skin Squamous Cell Carcinoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1

Interventions

pembrolizumab 151 Gemcitabine 137 Paclitaxel 128 Carboplatin 118 Bevacizumab 111 Surveys and Questionnaires 98 Docetaxel 96 Cisplatin 95 Cyclophosphamide 94 Exercise 89 Blood Specimen Collection 87 Nivolumab 84 Fluorouracil 75 Capecitabine 73 Dexamethasone 71 Radiotherapy 69 Irinotecan 62 Standard of Care 59 Pemetrexed 59 Oxaliplatin 57 Leucovorin 54 Drug Therapy 54 Cetuximab 48 Erlotinib Hydrochloride 46 atezolizumab 45 Sorafenib 44 Interviews as Topic 42 Doxorubicin 42 Ipilimumab 38 Magnetic Resonance Spectroscopy 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03767075 2024-04-25

BoB

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡